Skip to content
TheChatArchiveThe Chat Archive
gpt-3.5-turbo-0613· OpenAIHugging Face Arena Human Preference 55K

Patient Segment Extraction from Clinical Trial Information Introduction: This document…

From a Chatbot Arena battleThe same person sent this prompt to two anonymous models at once. Compare it with Microsoftwizardlm-70b’s answer.
  1. User

    Patient Segment Extraction from Clinical Trial Information

    Introduction: This document is designed to guide the extraction of patient segment information from a specified clinical trial.

    ** Definitions of line of therapy for reference:** LOT1 (Initial Line of Therapy): Definition: LOT1, also known as the Initial Line of Therapy or the First Line of Therapy, is the first treatment approach offered to individuals diagnosed with a specific medical condition. It is typically recommended for all patients, whether they have received one prior therapy or have not undergone any previous treatment. In this stage, healthcare providers use the primary or standard treatment options based on the condition and the patient's overall health.

    LOT2 (Second Line of Therapy): Definition: LOT2, or the Second Line of Therapy, becomes relevant when individuals do not respond adequately or have adverse reactions to the initial treatment (LOT1). Inclusion criteria for LOT2 may include references to prior treatment failures, inadequate responses, incomplete responses, loss of response, or intolerance to specific therapies. Depending on the condition, LOT2 may involve the use of alternative medications or therapeutic approaches that are different from LOT1.

    LOT3 (Third Line of Therapy): Definition: LOT3, or the Third Line of Therapy, is considered when patients continue to experience treatment failures, inadequate responses, or intolerances after both LOT1 and LOT2 interventions. Inclusion criteria for LOT3 may explicitly reference prior failures or inadequate responses to prior therapies. At this stage, healthcare providers explore more advanced or specialized treatment options, such as biologic therapies, targeted therapies, or other advanced medical interventions, tailored to the specific medical condition.

    Not Applicable (NA): Definition: In cases where the trial does not mention a specific LOT or involves patients with no prior therapy mentioned in the inclusion criteria, the assigned LOT value will be 'NA' (Not Applicable). 'NA' indicates that there is no specific therapy mentioned in the trial, and it may apply to situations where prior treatments or treatment failures are not referenced.

    Neoadjuvant: Definition: Neoadjuvant therapy refers to treatments given before the primary therapy. Common in cancer care, it includes therapies like chemotherapy, radiation, or hormone therapy administered prior to the main treatment, usually surgery. Its goal is to reduce the size or extent of the cancer before the main treatment, making it potentially easier to remove or cure.

    Adjuvant: Definition: Adjuvant therapy is treatment given after the primary therapy to increase the chances of a cure. In cancer care, adjuvant therapy may include chemotherapy, radiation, or hormone therapy administered after surgery, with the aim to eliminate any remaining cancer cells, reduce the risk of cancer recurrence, and improve survival rates.

    Grouped Dictionary for Mapping Phrases to LOT Values:

    • Neoadjuvant: Pre-Surgery, Neo-adjuvant, Treatment Naive neo-adjuvant, Resectable, Surgical Resection Candidates, Treatment Window Period,
    • Adjuvant: Adjuvant Therapy, Post-Preoperative Treatment, Complete Resection, Postoperative Adjuvant Chemotherapy
    • 1L : 1L Treatment, Chemotherapy-Naive, No Prior Advanced Disease Treatment, Post-Adjuvant Therapy, Treatment Naive, 1L Maintenance Therapy, Response to First-Line Treatment, Non-Progressors Post 1L, Alternative Treatment Options
    • 2L : 2L Treatment, One Prior Regimen for Metastatic Disease, Platinum-Based Therapy Failure, Prior Standard Therapy Receipt, Post First-Line Progression, Treatment After Failure, Received 1 to 2 Prior Therapies, Recurrent/Progressive Post Multimodal Therapy, 2L-Range Treatment
    • 3L : 3L Treatment, Two Prior Regimens, Received At Least 2 Systemic Therapies, Disease Progression Post 2 Treatments, Failed 2 Prior Regimens, 3L-Range Treatment
    • 4L: 4L Treatment, 4L-Range Treatment, Failed 3+ Prior Standard Therapies

    Instructions:

    1. Review the clinical trial information focusing on the inclusion and exclusion criteria.
    2. Extract key details relevant to the patient segment:
      • Line of Therapy (LOT): Defined above.
      • Disease Stage : Refers to how much a disease, such as cancer, has progressed. It helps in assessing the severity, prognosis, and guiding treatment options. Factors like tumor size, spread, and lymph node involvement are considered, like metastatic, Advanced.
      • Histology: Microscopic study of tissue to identify cell types in diseases. In cancer, it distinguishes types like Squamous, Non-Squamous, or Adenocarcinoma, guiding diagnosis and treatment.
      • Biomarkers: A biological molecule, substance, or characteristic that is objectively measured and evaluated as an indicator of normal physiological processes, pathological processes, or responses to therapeutic interventions, like KRASp.G12C mutation.
    3. Organize these details into a structured format for easy analysis.
    4. Utilize the provided dictionary to map specific phrases found in the clinical trial information to their corresponding LOT values. Cross-reference any terms related to therapy or treatment with the dictionary to ensure accurate LOT classification.
    5. If the model is not confident enough to provide a reliable or accurate output, please respond with 'Not Applicable'.
    6. Cross-reference all extracted patient segment details with the provided definitions to ensure accurate and contextual understanding of each segment's characteristics.

    Output Format: For each disease studied in the trial, provide the patient segment information in the following format(No extra explanation, only below output as mentioned):

    • Disease Name 1: \nLOT: ... \nStage: ... \nHistology: ... \nBiomarker: ...
    • Disease Name 2: \nLOT: ... \nStage: ... \nHistology: ... \nBiomarker: ... For example: Disease Name: NSCLC \nLOT: 3L \nStage: Metastatic \nHistology: Not Applicable \nBiomarker: KRASp.G12C mutation

    Please provide patient segment for below Clinical Trial Data, Title: "Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)"

    Inclusion Criteria: '''General Inclusion Criteria

    Male/female participants who are at least 18 years of age on the day of signing informed consent with advanced/metastatic cutaneous melanoma, NSCLC or MSS mCRC who meet the following criteria will be enrolled in this study. Male participants:

    o A male participant must agree to use a contraception during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period.

    Female participants:

    A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Not a woman of childbearing potential (WOCBP);OR A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment. Cohort 1 (MSS mCRC)

    MSS is defined as 0-1 allelic shifts among 3-5 tumor microsatellite loci using a PCR-based assay or immunohistochemistry. Must have received prior therapy with a fluoropyrimidine, oxaliplatin, and irinotecan. Prior treatment with an anti-PD-1/anti-PD-L1 or anti-CTLA-4 antibody is not allowed. Prior treatment with BRAF/MEK inhibitor therapy (if BRAF mutated) and/or EGFR targeted antibody (if KRAS WT) are allowed. No more than 2 prior lines of therapy for metastatic disease. Adjuvant therapy will count as 1 prior line of therapy if received within the prior 6 months; but if not does not count towards prior line of therapy. PIV (pan-immune-inflammation) cutoff of 1200 obtained on labs obtained during Screening. Cohort 2 (PD-1 R/R melanoma)

    PD-1 refractory disease as defined as progression on treatment with anti-PD-(L)1 inhibitor administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies. PD-1 treatment progression is defined by meeting all of the following criteria:

    Receipt of at least 2 doses of an approved or investigational anti-PD-(L)1 inhibitor. Demonstrated PD after anti-PD-(L)1 inhibitor as defined by RECIST v1.1. The initial evidence of PD is to be confirmed by a second assessment no less than 4 weeks from the date of the first documented PD, in the absence of rapid clinical progression (as defined by the criteria in the sub-point below). Progressive disease that has been documented within 12 weeks from the last dose of anti-PD-(L)1 inhibitor. Progressive disease is determined according to iRECIST. This determination is made by the investigator. Once PD is confirmed, the initial date of PD documentation will be considered the date of disease progression. Subjects who progressed on/within 3 months of adjuvant therapy with anti-PD-(L)1 inhibitor will be allowed; an adjuvant therapy will count as 1 prior line of therapy if received within the prior 6 months. Prior treatment with an anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) antibody is allowed but not required. Prior treatment with BRAF/MEK inhibitor therapy (if BRAF mutated) is allowed but not required. No more than 5 prior lines of therapy. Cohort 3 (PD-1 R/R NSCLC)

    PD-1 refractory disease as defined as progression on treatment with anti-PD-(L)1 inhibitor administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies. PD-1 treatment progression is defined by meeting all of the following criteria:

    Has received at least 2 doses of an approved or investigational anti-PD-(L)1 inhibitor. Has demonstrated PD after anti-PD-(L)1 inhibitor as defined by RECIST v1.1. The initial evidence of PD is to be confirmed by a second assessment no less than 4 weeks from the date of the first documented PD, in the absence of rapid clinical progression (as defined by the criteria in the sub-point below). Progressive disease has been documented within 12 weeks from the last dose of anti-PD-(L)1 inhibitor. Progressive disease is determined according to iRECIST. This determination is made by the investigator. Once PD is confirmed, the initial date of PD documentation will be considered the date of disease progression. Subjects who progressed on/within 3 months of adjuvant therapy with anti-PD-(L)1 inhibitor will be allowed; an adjuvant therapy will count as 1 prior line of therapy if received within the prior 6 months. Prior treatment with an anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) antibody is allowed but not required. Prior treatment with BRAF/MEK inhibitor therapy (if BRAF mutated) must have received and progressed or have demonstrable intolerance to approved targeted therapy. Patients with NSCLC with known oncogenic driver (including but not limited to EGFR, ALK, ROS, MET alterations) must have received and progressed past driver-specific therapy. No more than 5 prior lines of therapy. Other Criteria

    The participant (or legally acceptable representative if applicable) provides written informed consent for the trial. Have measurable disease based on RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. Have provided newly obtained core or excisional biopsy of a tumor lesion not previously irradiated to undergo tumor biopsy (core, punch, incisional or excisional).

    o Biopsy must meet minimal sampling criteria.

    Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 28 days prior to the date of enrollment. Adequate organ function. Screening labs obtained within 4 weeks of Cycle 1 day 1 Proteinuria exceeding 1gram in a 24 hour period. A pan-immune-inflammation (PIV) cutoff

  2. Assistant

    Disease Name: Melanoma LOT: Not Applicable Stage: Metastatic Histology: Not Applicable Biomarker: Not Applicable

    Disease Name: NSCLC LOT: 3L Stage: Not Applicable Histology: Not Applicable Biomarker: Not Applicable

    Disease Name: MSS mCRC LOT: 2L Stage: Not Applicable Histology: Not Applicable Biomarker: Not Applicable

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.